| __timestamp | Supernus Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 72471000 | 612613000000 |
| Thursday, January 1, 2015 | 89204000 | 650773000000 |
| Friday, January 1, 2016 | 106010000 | 619061000000 |
| Sunday, January 1, 2017 | 137905000 | 628106000000 |
| Monday, January 1, 2018 | 159888000 | 717599000000 |
| Tuesday, January 1, 2019 | 158425000 | 964737000000 |
| Wednesday, January 1, 2020 | 200677000 | 875663000000 |
| Friday, January 1, 2021 | 304759000 | 886361000000 |
| Saturday, January 1, 2022 | 377221000 | 997309000000 |
| Sunday, January 1, 2023 | 336361000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Takeda's SG&A expenses have shown a steady increase, peaking at approximately 1.05 trillion yen in 2023, reflecting a 72% rise from 2014. In contrast, Supernus Pharmaceuticals experienced a more volatile trajectory, with expenses surging by over 360% from 2014 to 2022, before a slight dip in 2023. This disparity highlights the contrasting strategies of a global giant versus a nimble player in managing operational costs. Notably, the data for 2024 is incomplete, indicating a need for further analysis to understand future trends. Such insights are invaluable for stakeholders aiming to optimize financial performance in the pharmaceutical sector.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? AbbVie Inc. or Supernus Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Protagonist Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Supernus Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Supernus Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.